- The European Medicines Agency: An Overview of Its Mission, Responsibilities, and Recent Initiatives in Cancer Drug Regulation
[作者:Pignatti, F; Gravanis, I; Herold, R; Vamvakas, S; Jonsson, B; Marty, M,期刊:Clinical Cancer Research, 页码:5220-5225 , 文章类型: Article,,卷期:2011年17-16]
- The European Medicines Agency (EMA) is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union (EU). Since 2005, the agency has become responsible for th...
- In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells
[作者:Chauhan, D; Tian, Z; Zhou, B; Kuhn, D; Orlowski, R; Raje, N; Richardson, P; Anderson, KC,期刊:Clinical Cancer Research, 页码:5311-5321 , 文章类型: Article,,卷期:2011年17-16]
- Purpose: The success of bortezomib therapy for treatment of multiple myeloma (MM) led to the development of structurally and pharmacologically distinct novel proteasome inhibitors. In the present study, we evaluated the ...
- Gastric Cancer Growth Control by BEZ235 In Vivo Does Not Correlate with PI3K/mTOR Target Inhibition but with [F-18]FLT Uptake
[作者:Fuereder, T; Wanek, T; Pflegerl, P; Jaeger-Lansky, A; Hoeflmayer, D; Strommer, S; Kuntner, C; Wrba, F; Werzowa, J; Hejna, M; Muller, M; Langer, O; Wacheck, V,期刊:Clinical Cancer Research, 页码:5322-5332 , 文章类型: Article,,卷期:2011年17-16]
- Purpose: In this study, we tested the antitumor activity of the dual phosphoinositide 3-kinase (PI3K)/mTOR inhibitor BEZ235 against gastric cancer in vitro and in vivo. Experimental Design: Gastric cancer cell lines (N87...
- Overcoming Antiangiogenic Resistance
[作者:Yao, JC; Phan, A,期刊:Clinical Cancer Research, 页码:5217-5219 , 文章类型: Editorial Material,,卷期:2011年17-16]
- The success of drugs targeting angiogenesis is tempered by the transient duration of disease control and modest survival improvement. The very hypoxic stress produced by successful therapy may lead to upregulation of mul...
- Role of Smac in Determining the Chemotherapeutic Response of Esophageal Squamous Cell Carcinoma
[作者:Xu, Y; Zhou, LP; Huang, J; Liu, F; Yu, J; Zhan, QM; Zhang, L; Zhao, XH,期刊:Clinical Cancer Research, 页码:5412-5422 , 文章类型: Article,,卷期:2011年17-16]
- Purpose: Second mitochondria-derived activator of caspase (Smac) regulates chemotherapy-induced apoptosis. Smac mimetics have been tested in clinical trials as chemosensitizers. We determined the role of Smac in modulati...
- Antitumor Activity of YM155, a Selective Small-Molecule Survivin Suppressant, Alone and in Combination with Docetaxel in Human Malignant Melanoma Models
[作者:Yamanaka, K; Nakahara, T; Yamauchi, T; Kita, A; Takeuchi, M; Kiyonaga, F; Kaneko, N; Sasamata, M,期刊:Clinical Cancer Research, 页码:5423-5431 , 文章类型: Article,,卷期:2011年17-16]
- Purpose: Aggressive cell growth and chemoresistance are notorious obstacles in melanoma therapy. Accumulating evidence suggests that survivin is preferentially expressed in cancer cells and plays a crucial role in cell d...
- Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90
[作者:Mehta, PP; Whalen, P; Baxi, SM; Kung, PP; Yamazaki, S; Yin, MJ,期刊:Clinical Cancer Research, 页码:5432-5442 , 文章类型: Article,,卷期:2011年17-16]
- Purpose: Triple-negative breast cancer (TNBC) patients have poor prognoses and survival outcomes such that the development of new targeted therapies is in strong demand. Mechanisms associated with high proliferation and ...
- Regression of Glioma in Rat Models by Intranasal Application of Parvovirus H-1
[作者:Kiprianova, I; Thomas, N; Ayache, A; Fischer, M; Leuchs, B; Klein, M; Rommelaere, J; Schlehofer, JR,期刊:Clinical Cancer Research, 页码:5333-5342 , 文章类型: Article,,卷期:2011年17-16]
- Purpose: In previous studies, we have shown that the apathogenic rat parvovirus H-1 (H-1PV) is capable to induce regression of advanced symptomatic rat and human gliomas in a rat model, when the virus was injected in the...
- Determinants of Successful CD8(+) T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice
[作者:Klebanoff, CA; Gattinoni, L; Palmer, DC; Muranski, P; Ji, Y; Hinrichs, CS; Borman, ZA; Kerkar, SP; Scott, CD; Finkelstein, SE; Rosenberg, SA; Restifo, NP,期刊:Clinical Cancer Research, 页码:5343-5352 , 文章类型: Article,,卷期:2011年17-16]
- Purpose: Adoptive cell transfer (ACT) of tumor infiltrating or genetically engineered T cells can cause durable responses in patients with metastatic cancer. Multiple clinically modifiable parameters can comprise this th...
- Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis
[作者:De Palma, M; Naldini, L,期刊:Clinical Cancer Research, 页码:5226-5232 , 文章类型: Article,,卷期:2011年17-16]
- Angiopoietin-2 (ANG2), a ligand of the TIE2 receptor, modulates endothelial cell biology and destabilizes blood vessels to facilitate angiogenesis. Recent reports have shown that ANG2 inhibition, for example, by monoclon...
- Prostate Cancer Immunotherapy
[作者:May, KF; Gulley, JL; Drake, CG; Dranoff, G; Kantoff, PW,期刊:Clinical Cancer Research, 页码:5233-5238 , 文章类型: Article,,卷期:2011年17-16]
- The interaction between the immune system and prostate cancer has been an area of research interest for several decades. The recent U. S. Food and Drug Administration approval of 2 first-in-class proof-of-concept immunot...
- SWOG Cooperative Group Biorepository Resource: Access for Scientific Research Studies
[作者:Hoban, CJ; Franklin, WA; Kopecky, KJ; Baker, LH,期刊:Clinical Cancer Research, 页码:5239-5246 , 文章类型: Article,,卷期:2011年17-16]
- SWOG (formerly the Southwest Oncology Group), a National Cancer Institute-supported cooperative group, conducts multi-institutional, multidisciplinary clinical trials for adult patients with cancer, covering a wide range...
- Prognostic Immune Markers in Non-Small Cell Lung Cancer
[作者:Suzuki, K; Kachala, SS; Kadota, K; Shen, RL; Mo, QX; Beer, DG; Rusch, VW; Travis, WD; Adusumilli, PS,期刊:Clinical Cancer Research, 页码:5247-5256 , 文章类型: Review,,卷期:2011年17-16]
- Tumor-associated immune responses have polarized effects in regulating tumor growth. Although a clear association has been shown between the tumor immune response and clinical outcome in colorectal and ovarian cancers, t...
- Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer
[作者:Glubb, DM; Cerri, E; Giese, A; Zhang, W; Mirza, O; Thompson, EE; Chen, PX; Das, S; Jassem, J; Rzyman, W; Lingen, MW; Salgia, R; Hirsch, FR; Dziadziuszko, R; Ballmer-Hofer, K; Innocenti, F,期刊:Clinical Cancer Research, 页码:5257-5267 , 文章类型: Article,,卷期:2011年17-16]
- Purpose: VEGF receptor 2 (VEGFR-2) plays a crucial role in mediating angiogenic endothelial cell responses via the VEGF pathway, and angiogenesis inhibitors targeting VEGFR-2 are in clinical use. As angiogenesis is a hos...
- PM02734 (Elisidepsin) Induces Caspase-Independent Cell Death Associated with Features of Autophagy, Inhibition of the Akt/mTOR Signaling Pathway, and Activation of Death-Associated Protein Kinase
[作者:Ling, YH; Aracil, M; Zou, YY; Yuan, ZQ; Lu, B; Jimeno, J; Cuervo, AM; Perez-Soler, R,期刊:Clinical Cancer Research, 页码:5353-5366 , 文章类型: Article,,卷期:2011年17-16]
- Purpose: PM02734 (elisidepsin) is a synthetic marine-derived cyclic peptide of the kahalalide family currently in phase II clinical development. The mechanisms of cell death induced by PM02734 remain unknown. Experimenta...
|